1-[2-(3-methylquinoxalin-2-ylsulfanyl)acetyl]-3-p-tolylurea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2-(3-methylquinoxalin-2-ylsulfanyl)acetyl]-3-p-tolylurea
• 英文别名: N-[(4-methylphenyl)carbamoyl]-2-(3-methylquinoxalin-2-yl)sulfanylacetamide
• 化学式: C₁₉H₁₈N₄O₂S
• 分子量: 366.444
• InChiKey: ANEYEOULSIHKKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  乙烷,三氯氟- 在 sodium acetate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 1-[2-(3-methylquinoxalin-2-ylsulfanyl)acetyl]-3-p-tolylurea
  参考文献：
  名称：

  Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

  摘要：

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.06.053

文献信息

• NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME
  申请人：THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

  公开号：US20170174678A1

  公开（公告）日：2017-06-22

  The present invention includes bicyclic compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
• Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress
  作者：H. Marie Loughran、Ziying Han、Jay E. Wrobel、Sarah E. Decker、Gordon Ruthel、Bruce D. Freedman、Ronald N. Harty、Allen B. Reitz

  DOI：10.1016/j.bmcl.2016.06.053

  日期：2016.8

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.